

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
11 November 2021 (11.11.2021)



(10) International Publication Number
WO 2021/226551 A1

(51) International Patent Classification:
C07K 14/705 (2006.01) A61P 37/00 (2006.01)

(21) International Application Number:
PCT/US2021/031430

(22) International Filing Date:
07 May 2021 (07.05.2021)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
63/022,373 08 May 2020 (08.05.2020) US
63/034,361 03 June 2020 (03.06.2020) US
63/080,643 18 September 2020 (18.09.2020) US

(71) Applicant: ALPINE IMMUNE SCIENCES, INC.
[US/US]; 188 East Blaine Street, Suite 200, Seattle, Wash-
ington 98102 (US).

(72) Inventors: DILLON, Stacey; 188 East Blaine Street, Suite
200, Seattle, Washington 98102 (US). RIXON, Mark; 188
East Blaine Street, Suite 200, Seattle, Washington 98102
(US). EVANS, Lawrence; 188 East Blaine Street, Suite
200, Seattle, Washington 98102 (US). DEMONTE, Daniel
William; 188 East Blaine Street, Suite 200, Seattle, Wash-
ington 98102 (US). KUIJPER, Joseph L.; 188 East Blaine

Street, Suite 200, Seattle, Washington 98102 (US). PENG,
Stanford L.; 188 East Blaine Street, Suite 200, Seattle,
Washington 98102 (US).

(74) Agent: POTTER, Karen et al.; Morrison & Foerster LLP,
12531 High Bluff Drive, Suite 100, San Diego, California
92130-2040 (US).

(81) Designated States (unless otherwise indicated, for every
kind of national protection available): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ,
CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO,
DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN,
HR, HU, ID, IL, IN, IR, IS, IT, JO, JP, KE, KG, KH, KN,
KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD,
ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO,
NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW,
SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN,
TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.


(84) Designated States (unless otherwise indicated, for every
kind of regional protection available): ARIPO (BW, GH,
GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ,
UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ,
TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK,
EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV,
MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM,

(54) Title: APRIL AND BAFF INHIBITORY IMMUNOMODULATORY PROTEINS AND METHODS OF USE THEREOF

(57) Abstract: Provided herein are immunomodulatory proteins that exhibit neu-
tralizing activity of BAFF and APRIL (or BAFF/ APRIL heterotrimers). The im-
munomodulatory proteins provided herein include variant domains of Transmem-
brane Activator and CAML Interactor (TACI). Among provided immunomodulatory
proteins are TACI-Fc fusion proteins. Also provided are nucleic acid molecules en-
coding the immunomodulatory proteins. The immunomodulatory proteins provide
therapeutic utility for a variety of immunological diseases, disorders or conditions.
Also provided are compositions and methods for making and using such proteins.

FIG. 8B

Soluble TACI-Fc



WO 2021/226551 A1

[Continued on next page]

TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW,
KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

- *as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))*

Published:

- *with international search report (Art. 21(3))*
- *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))*
- *with sequence listing part of description (Rule 5.2(a))*